Evidence map›Paper›PMID 38267559›Full record

ArticleAnnals of hematology2024

Real-world outcome of patients with extensively pretreated multiple myeloma who were treated with selinexor and dexamethasone: a Korean multicenter retrospective analysis.

Jun Ho Yi, Sung-Soo Park, Chang-Ki Min, Hyeon-Seok Eom, Ja Min Byun, Youngil Koh, Sung-Soo Yoon, Jae Hoon Lee, Sung-Hoon Jung, Je-Jung Lee and 3 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jun Ho Yi *Division of Hematology-Oncology, Department of Medicine, Chung-Ang University, Seoul, Korea.
Sung-Soo Park *Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, Catholic University, Seoul, Korea.
Chang-Ki MinDepartment of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, Catholic University, Seoul, Korea.
Hyeon-Seok EomDepartment of Internal Medicine, National Cancer Center, Goyang, Korea.
Ja Min ByunDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Youngil KohDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Sung-Soo YoonDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Jae Hoon LeeDepartment of Hematology, Gachon University College of Medicine, Incheon, Korea.
Sung-Hoon JungDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital and Chonnam National University Medical School, Hwasun-gun, Jeollanam-do, Korea.
Je-Jung LeeDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital and Chonnam National University Medical School, Hwasun-gun, Jeollanam-do, Korea.
Sang Eun YoonDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul, 06351, Korea.
Sook-Young WooBiomedical Statistics Center, Data Science Research Institute, Research Institute for Future Medicine, Samsung Medical Center, Seoul, Korea.
Kihyun KimDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul, 06351, Korea. kihyunkimk@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The outcomes of patients with myeloma after exposed to penta-classes are extremely poor. Selinexor is the first approved exportin inhibitor for those patients, but intractable toxicities may limit its use. This retrospective study evaluated the real-world efficacy and safety of selinexor plus dexamethasone (XD) and involved 48 patients with multiple myeloma, who were treated from November 2020 to October 2022. Their median age was 64 years, and the median number of prior lines of therapy was 6. The overall response rate was 25%, and the median progression-free survival (PFS) was 2.1 months (95% confidence interval (CI), 1.7-2.5). Patients on a reduced initial dose, delayed treatment, and dose reduction had better PFS. After XD treatment failure, 17 patients received subsequent therapy and had a median PFS of 2.4 months. The median overall survival was 4.6 months (95% CI, 2.3-6.9). Among the patients, 12 (25%) and 17 (35%) experienced dose reduction and delayed treatment, respectively. Our data show that the real-world efficacy of XD treatment in heavily pretreated patients was modest and that improving treatment adherence through reducing initial doses or delaying treatments may improve patient outcomes.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsDexamethasoneHydrazinesMultiple MyelomaTriazolesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRepublic of KoreaRetrospective StudiesSurvival RateTreatment OutcomeDexamethasoneHydrazinesselinexorTriazolesMultiple myelomaPrognosisSelinexor

Identifiers

PMID38267559

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.